Ken Griffin Harpoon Therapeutics, Inc. Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.55 - $0.82 $3,505 - $5,225	6,373 New	6,373 $4,000
Q4 2022 Feb 14, 2023	BUY	$0.6 - $1.41 $8,674 - $20,384	14,457 New	14,457 $10,000
Q2 2022 Aug 15, 2022	BUY	$1.78 - $5.02 $198,991 - $561,200	111,793 Added 635.08%	129,396 $247,000
Q4 2021 Feb 14, 2022	SELL	$5.69 - $7.83 $257,910 - $354,910	-45,327 Reduced 72.03%	17,603 $132,000
Q3 2021 Nov 15, 2021	BUY	$7.88 - $14.0 $286,540 - $509,082	36,363 Added 136.87%	62,930 $497,000
Q2 2021 Aug 16, 2021	SELL	$13.81 - $23.25 $3,922 - $6,603	-284 Reduced 1.06%	26,567 $368,000
Q1 2021 May 17, 2021	BUY	$17.65 - $24.16 $84,984 - $116,330	4,815 Added 21.85%	26,851 $562,000
Q4 2020 Feb 16, 2021	SELL	$12.83 - $17.84 $361,138 - $502,160	-28,148 Reduced 56.09%	22,036 $366,000
Q3 2020 Nov 16, 2020	BUY	$11.01 - $18.52 $43,632 - $73,394	3,963 Added 8.57%	50,184 $853,000
Q2 2020 Aug 14, 2020	BUY	$11.11 - $24.72 $513,515 - $1.14 Million	46,221 New	46,221 $768,000

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.